CERVOMED INC (CRVO)
US15713L1098 - Common Stock
CERVOMED INC
NASDAQ:CRVO (12/6/2024, 8:00:00 PM)
After market: 12.5101 +0.6 (+5.04%)11.91
+2.19 (+22.53%)
Company Profile
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-11-09. The company is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. The company is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Company Info
CERVOMED INC
20 Park Plaza, Suite 424
Boston MASSACHUSETTS
P: 16177444400
Employees: 8
Website: https://cervomed.com/
CRVO News
2 days ago - Market News VideoFriday Sector Leaders: Biotechnology, Apparel Stores11 days ago - CervoMed Inc.CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal DementiaDesignation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On...
26 days ago - CervoMed Inc.CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies...
a month ago - CervoMed Inc.CervoMed Awarded the Prix Galien USA 2024 Prize for Best StartupThe Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their...
a month ago - CervoMed Inc.CervoMed to Participate in Upcoming Investor ConferencesBOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
a month ago - CervoMed Inc.CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust...
CRVO Twits
Here you can normally see the latest stock twits on CRVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
